Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Deciphera Pharmaceuticals, Inc.    DCPH

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/07/2019 10/08/2019 10/09/2019 10/10/2019 10/11/2019 Date
33.75(c) 31.88(c) 31.7(c) 32.54(c) 32.54(c) Last
248 625 390 294 163 261 228 914 374 009 Volume
-1.83% -5.54% -0.56% +2.65% 0.00% Change
More quotes
Financials (USD)
Sales 2019 25,6 M
EBIT 2019 -174 M
Net income 2019 -169 M
Finance 2019 361 M
Yield 2019 -
Sales 2020 10,8 M
EBIT 2020 -217 M
Net income 2020 -214 M
Finance 2020 335 M
Yield 2020 -
P/E ratio 2019 -7,93x
P/E ratio 2020 -6,96x
EV / Sales2019 50,4x
EV / Sales2020 121x
Capitalization 1 648 M
More Financials
Company
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of... 
More about the company
Surperformance© ratings of Deciphera Pharmaceuticals,
Trading Rating : Investor Rating : -
More Ratings
Latest news on DECIPHERA PHARMACEUTICALS,
10/02DECIPHERA PHARMACEUTICALS : Appoints Matthew L. Sherman, M.D. as Executive Vice ..
BU
10/01DECIPHERA PHARMACEUTICALS : Announces Late-Breaking Oral Presentation at the ESM..
AQ
09/30DECIPHERA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements..
AQ
09/30DECIPHERA PHARMACEUTICALS : Announces Late-Breaking Oral Presentation at the ESM..
BU
09/25DECIPHERA PHARMACEUTICALS, INC. : to Present at the 2019 Cantor Global Healthcar..
BU
09/06DECIPHERA PHARMACEUTICALS : Announces Late-Breaking Oral Presentation of Pivotal..
AQ
09/05DECIPHERA PHARMACEUTICALS : Announces Late-Breaking Oral Presentation of Pivotal..
BU
09/03DECIPHERA PHARMACEUTICALS : Announces Full Exercise of Underwriters' Option to P..
BU
08/19DECIPHERA PHARMACEUTICALS : Announces Closing of Public Offering of Common Stock
BU
08/15DECIPHERA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Ot..
AQ
More news
Sector news : Bio Therapeutic Drugs
10/10GILEAD SCIENCES : Galapagos See Efficacy in Advanced Rheumatoid Arthritis Study
DJ
10/10Snakes and ladders - SoftBank Vision Fund's climbing, sliding valuations
RE
10/09BAYER : to Advance Ionis Pharma's Clotting Medicine
DJ
10/08Thermo Fisher Scientific Sees Largest Percent Decrease Since October 2011 -- ..
DJ
10/08Qiagen CEO quits amid genetic sequencing U-turn, shares tumble
RE
More sector news : Bio Therapeutic Drugs
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 51,18  $
Last Close Price 32,54  $
Spread / Highest target 103%
Spread / Average Target 57,3%
Spread / Lowest Target -10,9%
EPS Revisions
Managers
NameTitle
Steven L. Hoerter President, CEO & Independent Director
James A. Bristol Chairman
Thomas P. Kelly Chief Financial Officer
Daniel L. Flynn Chief Scientific Officer
Stephen B. Ruddy Chief Technical Officer
Sector and Competitors
1st jan.Capitalization (M$)
DECIPHERA PHARMACEUTICALS, INC.55.03%1 648
GILEAD SCIENCES2.30%81 040
VERTEX PHARMACEUTICALS2.72%44 315
REGENERON PHARMACEUTICALS-19.47%32 911
WUXI APPTEC CO., LTD.65.75%20 242
GENMAB23.89%12 836